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Abstract
Background: Primary mucinous carcinoma of the thyroid gland is a rare disease; only 6 cases of primary mucinous
carcinoma of the thyroid have been previously reported. Primary mucinous carcinoma of the thyroid gland with
incomplete tumor resection tends to be associated with a poor prognosis, resulting in death within a few months.
An early and appropriate diagnosis may contribute to improvement in patient prognosis; however, it is extremely
difficult to diagnose primary mucinous carcinoma of the thyroid. We present the seventh reported case of primary
mucinous carcinoma in the thyroid gland; moreover, rhabdoid cells were detected, which, to our knowledge, is a
novel finding.
Case presentation: An 81-year-old Japanese woman was initially diagnosed with a poorly differentiated thyroid
carcinoma, and she underwent a hemithyroidectomy. Pathological examination revealed the presence of abundant
mucus and agglomeration of large atypical cells. Rhabdoid cells were also seen scattered among the tumor cells.
Immunostaining was performed for various markers, and on the basis of these results, we diagnosed the lesion as
primary mucinous carcinoma with rhabdoid cells in the thyroid gland. Ten months after surgery, recurrence was
noted in the paratracheal lymph nodes; therefore, total resection of the residual thyroid gland and paratracheal
lymphadenectomy with thyroid-stimulating hormone suppression were performed. The patient is currently alive
and disease-free.
Conclusions: The current case is of interest not only because of the rare histological findings, but also because the
patient achieved long-term survival following diagnosis of a mucinous carcinoma. We believe this report will be
helpful for diagnosing future cases of mucinous carcinoma of the thyroid.
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Background
Mucinous carcinomas are characterized by an abundant
extracellular production of mucus. They are usually
detected in the breast, colon, stomach, and pancreas. At
these sites, incidence rates range from 1 % to 5 % [1, 2].
Primary mucinous carcinomas of the thyroid gland are
extremely rare. Since the first report published by Diaz
et al. in 1976, only 6 such case reports were identified
during our search of the PubMed database [3–8]. Fur-
thermore, primary mucinous carcinoma of the thyroid
gland with rhabdoid cells has never been previously re-
ported. Here, we describe our experience with the first
reported case of primary mucinous carcinoma of the
thyroid gland with rhabdoid cells and discuss our find-
ings in the context of the extant literature.
Case presentation
An 81-year-old woman presented with a mass that had
grown rapidly over a few days at the Kyushu Central
Hospital of the Mutual Aid Association of Public School
Teachers.
Computed tomography (CT) revealed a mass in the
thyroid gland invading the muscles in the anterior region
of the neck (Fig. 1). Paratracheal lymph nodes metastasis
was also detected. However, no lateral cervical lymph
node metastasis or distant metastasis was detected on
CT and positron emission tomography. On the basis of
cytology findings, poorly differentiated carcinoma was sus-
pected. Additional systematic laboratory tests indicated
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normal thyroid function (thyroid-stimulating hormone
[TSH] 4.0 IU/mL, F-T4 0.77 ng/dL), calcium levels
(9.8 mg/dL), carcinoembryonic antigen (CEA) levels
(0.5 ng/mL), and calcitonin levels (25 pg/mL); none of
the findings indicated medullary carcinoma. However,
the thyroglobulin (TG) level was slightly elevated at
98.4 ng/mL (normal range: <30 ng/mL). A poorly dif-
ferentiated thyroid carcinoma was diagnosed, and
hemithyroidectomy with central cervical lymphadenec-
tomy was performed.
Pathological examination of the surgical specimen
revealed abundant mucus as a characteristic finding
(Fig. 2a). Agglomerations of large atypical cells were also
detected (Fig. 2b). The large tumor cells had large atyp-
ical nuclei and a relatively high frequency of mitotic fig-
ures. Of note, rhabdoid cells with cytoplasmic inclusion
bodies were detected scattered among the tumor cells.
There were no nuclear grooves or intranuclear inclu-
sions characteristic of papillary carcinoma, no papillary
or follicular structure, and no necrosis or calcification.
The extracellular mucus stained diffusely with Alcian
blue staining (Fig. 2c), mucicarmine staining (Fig. 2d),
and periodic acid–Schiff (PAS) staining, and these find-
ings confirmed the epithelial origin of the mucin. In
addition, the tumor cells stained positive for AE1/AE3,
confirming the epithelial nature of the tumor. Thyroid
transcription factor-1 (TTF-1) and TG staining was also
positive, confirming the tumor’s ability to differentiate
into thyroid tissue (Fig. 2e, f ). To confirm whether
the tumor was a medullary carcinoma, staining for
Fig. 1 Computed tomography of mass in the thyroid gland.
The invasion of muscles in the anterior region is indicated with
an arrow
Fig. 2 Pathological and immunohistochemical staining resulting in the diagnosis of primary mucinous carcinoma. a A large pool of
extracellular mucin (hematoxylin-eosin, 10×). b Abundant mucus with large atypical cells (hematoxylin-eosin, 40×; the arrows point to the
extracellular mucin). c: Mucinous material positive with Alcian blue staining. d Mucinous material positive with mucicarmine staining. e
Tumor cells immunoreactive for thyroid transcription factor-1 (immunoperoxidase, 10×). f Tumor cells immunoreactive for thyroglobulin
(immunoperoxidase, 40×)
Matsuo et al. Diagnostic Pathology  (2016) 11:48 Page 2 of 5
calcitonin and CEA was also performed, but the results
were negative. MIB-1 expression was moderately positive
(40 %). The cytoplasmic inclusion bodies of some of the
tumor cells were positive for vimentin, indicating that
the cells were rhabdoid cells (Fig. 3a, b). On the basis of
the above-mentioned findings, a primary mucinous car-
cinoma of the thyroid gland with rhabdoid cells was
diagnosed.
Ten months after the surgery, recurrence was de-
tected in the contralateral paratracheal lymph node
(Fig. 4). Accordingly, total resection of the residual thy-
roid gland and paratracheal lymphadenectomy were
performed. TSH suppression therapy was initiated as
adjuvant therapy. Six years after treatment for the re-
lapse, the patient is alive and disease-free. The TG
levels decreased to <5.0 ng/mL after the surgery and
have not increased subsequently, not even at the time
of the relapse.
Conclusions
Mucinous carcinomas are cancers characterized by an
abundant extracellular production of mucus. A definitive
diagnosis of primary mucinous carcinoma of the thyroid
gland is difficult to establish, as some types of papillary
carcinomas, follicular carcinomas, medullary carcin-
omas, and thyroid metastases from cancers of other or-
gans also produce mucin, which is an important feature
of primary mucinous carcinomas of the thyroid gland
[5–7]. Various tests, including immunostaining, need to
be performed to establish a pathological diagnosis of
mucinous carcinoma and to confirm that the mucin in
extracellular mucus is produced by the epithelium [4].
In the case described here, 3 staining methods, namely
Alcian blue, mucicarmine, and PAS staining, were used
to confirm the production of mucin in the mucus by the
epithelium. Next, other histological types of mucus-
producing tumors were ruled out. For example, papillary
carcinoma and follicular carcinoma were ruled out based
on the absence of follicular and papillary structures, the
absence of hyaline nuclei or nuclear grooves, and the ab-
sence of intranuclear cytoplasmic inclusion bodies. Me-
dullary carcinoma was ruled out based on the absence of
amyloid deposits in the interstitial space between the cell
aggregates and negative immunostaining for CEA and
calcitonin. Also, positive TG and TTF-1 staining con-
firmed that the tumor originated from the thyroid gland
and had the ability to differentiate into thyroid tissue,
thus ruling out the possibility of a thyroid metastasis
from a mucinous carcinoma of another organ. Finally,
the tumor cells showed positive AE1/AE3 staining, pro-
viding further evidence of the epithelial nature of the
tumor. Clinically, a primary mucinous carcinoma of the
thyroid gland was diagnosed because no other primary
tumor was detected on a whole-body scan, and similar
tumor metastases were detected at the central cervical
lymph nodes.
The characteristics of the 6 previously reported cases
as well as the case described here are presented in
Table 1. Lymph node metastasis was detected at the ini-
tial diagnosis in a high proportion of cases (6 of 7 cases).
Furthermore, distant metastases developed in 3 out of 7
cases, and most patients died of the disease (5 of 7
cases); those who underwent incomplete resection died
within a few months, demonstrating a poor prognosis
[3–8]. Therapeutic methods for recurrence included sur-
gery, iodine therapy, radiation therapy, and anticancer
drug therapy, but none of these were reported to be ef-
fective [4–6]. Therefore, complete resection during the
initial treatment appears to be the most effective treat-
ment option.
In the case reported here, additional surgery for ab-
lation of the residual thyroid gland and prophylactic
cervical lymphadenectomy were not performed ini-
tially because of the patient’s refusal to undergo these
Fig. 3 Pathological and immunohistochemical staining for the detection of rhabdoid cells. a Rhabdoid cells (hematoxylin-eosin 40×, arrow).
b Rhabdoid cells positive for vimentin (arrow)
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procedures. However, local recurrence developed
10 months later, and complete resection of the re-
sidual thyroid gland with TSH suppression was per-
formed; no recurrence has been noted for 6 years.
TSH suppression was continued, as the tumor cells
had a tendency to differentiate into TG-producing
cells and could express TSH receptors, as evidenced
by positive TG staining and a decrease in TG levels
to <5.0 ng/mL after tumor resection. Although the
extent of the contribution of TSH suppression ther-
apy to the prognosis in the case presented here re-
mains unclear, the long-term survival suggests that
TSH suppression therapy may be a suitable option for
postoperative adjuvant therapy for mucinous carcin-
oma in selected cases.
Rhabdoid cells are large polygonal cells that contain
an intracellular eosinophilic hyaline substance, and these
cells are immunohistochemically positive for vimentin
and keratin. These cells have been reported to be de-
tected in various types of malignant tumors. It has been
suggested that rhabdoid cells represent a stage of cellular
degeneration or a preliminary stage before apoptosis or
cell necrosis [9]. There are also few reports on the pres-
ence of these cells in thyroid cancer. In all cases, the
presence of rhabdoid cells has been reported as an indi-
cator of poor prognosis [10–12].
Histologically, the case described here was also pre-
dicted to have a poor prognosis; however, long-term sur-
vival of 6 years has been achieved. We encountered a
rare case of primary mucinous carcinoma of the thyroid
gland; the presence of rhabdoid cells, which are rarely
found in thyroid carcinomas, was also observed. To our
knowledge, this is the first report to describe the pres-
ence or rhabdoid cells in a primary mucinous carcinoma
of the thyroid. Histopathologically, this case is extremely
rare, and clinically, long-term survival in such cases is
also very rare, but this was achieved with complete
tumor resection and TSH suppression therapy in this
case. The pathological diagnosis of primary mucinous
carcinoma of the thyroid gland is difficult to determine
and requires thorough histopathological analyses. In
addition, prompt and complete resection of the tumor
immediately after the diagnosis may be the most effect-
ive treatment strategy.
Table 1 Summary of seven case studies with primary mucinous carcinoma
First author (year) Age/sex LN/distant
metastasis
Treatment Prognosis
Diaz [3] (1976) 44/M No/No Hemithyroidectomy immediately after diagnosis,
followed by total thyroidectomy + ND
7y NED
Sobrinho [4] (1986) 56/M Yes/No Total thyroidectomy + ND 1y Recurrence (intestinal tract and lungs)
Tx: RT and CH (5FU)
2y DOD
Cruz [5] (1991) 32/F Yes/No Total thyroidectomy + ND 2 m Recurrence (thyroid gland, skin, and lungs)
Tx: iodine therapy, RT, CH (BLM, VCR, ADM)
8 m DOD
Kondo [6] (2005) 82/F Yes/No Hemithyroidectomy + ND 2y Recurrence (LN and skin)
Tx: surgery and iodine therapy
4y DOD
Antonio [7] (2007) 62/F Yes/No Total thyroidectomy + ND (incomplete resection) 6 m DOD
Mnif [8] (2013) 56/M Yes/No Total thyroidectomy + ND (incomplete resection) 1 m DOD
Present case 81/F Yes/No Hemithyroidectomy 10 m Recurrence(LN)
Tx: Total thyroidectomy+ TSH suppression therapy
6y NED
M male, F female, LN lymph node, ND neck dissection, NED no evidence of disease, DOD died of disease, RT radiotherapy, CH chemotherapy, 5FU 5-fluorouracil, Tx
treatment, BLM bleomycin, VCR vincristine, ADM adriamycin
Fig. 4 Computed tomography indicating recurrence in the
paratracheal lymph node. The paratracheal lymph node is
indicated with an arrow
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